While in vivo CAR-T therapies eliminate complex ex vivo manufacturing, they introduce a new critical variable: the patient's own immune system. The therapy's efficacy relies on modifying T-cells within the body, but each patient's immune status is different, especially after prior treatments. This makes optimizing and standardizing the dose a significant challenge compared to engineered cell therapies.

Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.

The hype around in-vivo CAR-T overlooks that it's a more complex form of gene therapy. It relies on the same delivery vectors (AAVs, LNPs) that have caused patient deaths and off-target effects like liver concentration in simpler gene therapies, suggesting a difficult path to success.

Companies developing therapies with novel components like membrane proteins must navigate CMC development without established regulatory guidance. Unlike well-understood biologics like monoclonal antibodies, the lack of precedent in databases creates unique challenges for defining processes and satisfying regulatory bodies, requiring pioneers to set the standards.

To secure investment in the high-risk neurodegeneration space, companies must avoid significant 'leaps of faith.' A key de-risking factor is applying novel modalities to clinically validated pathways. This provides a stronger scientific foundation than pursuing a completely unproven biological hypothesis, making the venture more compelling to investors.

While scientifically exciting, pioneering a new biological pathway makes investors more conservative, as there is no proven path to follow. K-36's CEO notes this paradox: it requires more effort to educate investors and define a new space compared to a 'fast-follower' company with a clearer, pre-validated market.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

When developing a novel platform with no regulatory precedent, the key is to present a robust scientific case to agencies. This involves educating them with comprehensive data and explaining the 'why' behind your approach, rather than simply trying to fit into existing guidelines that may not apply.

Instead of managing symptoms, the company's mRNA CAR-T therapy eliminates sensitized mast cells. This allows the body to repopulate with new, non-sensitized cells, aiming to permanently reset the immune system's allergic response at its cellular source, a strategy borrowed from cancer immunotherapy.